Saxenda vs. Ozempic weight loss journeys: what TikTok skips

What did @juliagabriele200 actually say?

Honestly? The transcript here is nearly impossible to parse as coherent medical or weight loss content. The words attributed to this video read like a garbled auto-transcription, full of disconnected phrases about buildings, games, and patience, with no discernible claims about Saxenda, Ozempic, or weight loss at all. The caption tells us this is a weight loss progress video using the hashtags #saxenda, #ozempic, and #emagrecimento (Portuguese for weight loss), but the transcript itself does not deliver any specific claims we can directly fact-check.

What we can say is that the video appears to document a personal GLP-1 medication journey, likely liraglutide (Saxenda) or semaglutide (Ozempic or Wegovy), given the hashtags. Progress or "before and after" style content on these medications is extremely common on TikTok and has driven significant public interest in GLP-1 receptor agonists since 2022. The 735,000-plus views suggest the content resonated visually even if the audio record is unreliable.

Does the science back this up?

The general premise of GLP-1 medications producing meaningful weight loss is well supported by clinical evidence. This is one of the more robustly studied drug classes in recent memory, and the effect sizes are not trivial.

Liraglutide (Saxenda) at 3.0 mg daily produced an average weight loss of 8 percent of body weight compared to 2.6 percent with placebo in the SCALE Obesity and Prediabetes trial (Pi-Sunyer et al., 2015, New England Journal of Medicine). Semaglutide (Wegovy, the weight loss formulation distinct from Ozempic) performed even better. The STEP 1 trial (Wilding et al., 2021, NEJM) showed participants lost an average of 14.9 percent of body weight over 68 weeks on 2.4 mg weekly semaglutide.

Ozempic specifically is FDA-approved for type 2 diabetes management, not weight loss. Using it off-label for weight loss is common but worth noting, since the approved weight loss formulation is Wegovy, which uses the same molecule at a higher dose. These are not the same product.

What did they get wrong (or right)?

Because the transcript is effectively unintelligible, we cannot attribute specific errors to this creator. What we can flag is what often goes wrong in this content category on TikTok, and what creators sometimes get right by accident or experience.

Common errors in GLP-1 progress content include conflating Ozempic (diabetes drug) with Wegovy (weight loss drug) as if they are interchangeable. They share semaglutide as the active ingredient, but dosing protocols and regulatory approvals differ. That distinction matters clinically and legally.

Personal progress documentation, when it stays in its lane, is actually useful. Lived experience data from real patients helps normalize treatment-seeking and reduces stigma around medically supervised weight management. A 2023 study (Butner et al., 2023, Obesity Science and Practice) found patient-generated content about GLP-1 therapies significantly influenced treatment initiation decisions, for better and worse.

We are not in a position to say this creator did anything medically irresponsible based on what we can read. We are also not in a position to endorse the content, given we cannot verify what was actually said.

What should you actually know?

If you are watching GLP-1 progress videos on TikTok, here is what the evidence actually tells you.

• Saxenda (liraglutide) and Ozempic (semaglutide) are different drugs with different mechanisms, dosing schedules, and regulatory approvals. Do not assume a video about one applies to the other.
• Weight loss results vary significantly between individuals. The averages from clinical trials are population-level estimates. Some people lose more. Some lose less. Some lose nothing.
• GLP-1 medications require a prescription and medical oversight. Side effects including nausea, vomiting, pancreatitis risk, and thyroid concerns are real and require clinical monitoring (Davies et al., 2021, Lancet Diabetes and Endocrinology).
• Compounded semaglutide, which has been widely available during shortage periods, is not clinically equivalent to brand-name Wegovy or Ozempic. The FDA has been explicit about this. Do not assume they are the same product based on TikTok content.
• If a video makes you want to start or change a GLP-1 regimen, that conversation belongs with a licensed clinician, not a comment section.